Mavorixafor trihydrochloride

A CXCR4 antagonist

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
2mg

￥987.00

790.00

- +
5mg

￥1525.00

1220.00

- +
10mg

￥2725.00

2180.00

- +
50mg

￥9175.00

7340.00

- +
100mg

￥14962.00

11970.00

- +
200mg

￥0.00

0.00

- +
500mg

￥0.00

0.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Mavorixafor is a chemokine (C-X-C motif) receptor 4 (CXCR4) antagonist (IC₅₀ = 13 nM in a radioligand binding assay).¹ It is selective for CXCR4 over chemokine (C-C motif) receptor 1 (CCR1), CCR2b, CCR4, CCR5, CXCR1, and CXCR2 (IC₅₀s = >10 ?M for all). Mavorixafor reduces chemotaxis of CCRF-CEM T cells induced by chemokine (C-X-C motif) ligand 12 (CXCL12; IC₅₀ = 19 nM).² It inhibits fusion of CHO-K1 cells expressing gp120 to P4-P5 MAGI cells with an IC₅₀ value of 1.5 nM. It decreases HIV-1 NL4.3 viral replication in MT-4 cells and isolated human peripheral blood mononuclear cells (PBMCs; IC₅₀s = 2 and 9 nM, respectively).¹

1.Skerlj, R.T., Bridger, G.J., Kaller, A., et al.Discovery of novel small molecule orally bioavailable C–X–C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replicationJ. Med. Chem.53(8)3376-3388(2010) 2.Mosi, R.M., Anastassova, V., Cox, J., et al.The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitorBiochem. Pharmacol.83(4)472-479(2012)